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Almtract 
A large number of cytokines have b en shown to possess a four-helix bundle structure with a unique up-up-down-down connectivity. The receptors 
for this family of cytokines have been shown to be homologous as well, each possessing two tandem repeats of a fihroneetin type III-like domain. 
The crystal structure of human growth ormone bound to the soluble portion of its receptor has served as the only experimentally-determined example 
of the interaction between the four-helix bundle cytokines and their receptors: two identical receptor subunits bind to different epitopes on the same 
growth hormone ligand. We have conducted a series of experiments to determine if this structural paradigm istrue for interleuldn-4 and interleuldn-4 
receptor. Native polyaerylamide g l electrophoresis and gel filtration chromatography reveal that interleukin-4 forms a tight 1:1 complex with the 
soluble portion of interleukin-4 receptor and is thus unlike the growth hormone system. 
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1. Introduction 
Human intedeukin-4 (hIL-4) is a 129 residue, T lym- 
phocyte-der ived cytokine which induces a large number 
of biological effects, activities centered around the stimu- 
lation of proliferation and differentiation f a variety of 
cell types (for reviews see [1]). IL-4 belongs to a large 
family of structurally homologous cytokines, each com- 
posed of a four-helix bundle. The helices are connected 
with the up-up-down-down topology unique to the fam- 
ily, one which can be further divided into a 'short' group 
containing on average 120-130 residues (IL-2, IL-4, 
GM-CSF) [2] and a 'long' group containing on average 
180 residues (GH, IL-6, G-CSF, Onco M). The structure 
of IL-4 has been determined by four independent efforts 
yielding two NMR solution structures [3,4] and two crys- 
tal structures [5,6]. These have been compared in detail 
[7] and with other helical cytokines [8]. 
Mature human interleukin-4 receptor (hIL-4R) is an 
800 residue protein with an extracellular domain of 
about 207 residues, a transmembrane domain of 24resi- 
dues, and an intracellular domain of 569 residues [9]. The 
receptor binds IL-4 with high affinity (Kd ~ 100 pM) and 
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transfection of the hIL-4R eDNA into a murine T cell 
line is sufficient for conferring biological responsiveness 
to IL-4 [10]. Although no structure of hIL-4R has yet 
been determined experimentally, the extraceilular do- 
main shares ignificant sequence homology with a large 
number of cytokine, hormone, and neurotrophic factor 
receptors [11,12]. Members of this receptor superfamily 
all contain a tandem repeat of ~ 100 residue modules in 
their extracellular domains proposed to fold into fi- 
bronectin type III-like domains [13]. It is these modules 
that recogniTe the four-helix bundle cytokines leading to 
signal transduction. 
At present he growth hormone system is the only 
cytokine-receptor c mplex for which the high resolution 
structure has been determined, and it has served as the 
structural paradigm for interactions between the four- 
helix bundle cytokines and their receptors. The structure 
of the human growth hormone (hGH) bound to the ex- 
tracellular domain of human growth hormone receptor 
(hGHR) was solved by X-ray crystallography at 2.8 A 
resolution by de Vos et al. [14]. The receptor structure 
reveals that the two tandem 100-residue modules con- 
served in the receptor family fold into two fibronectin 
type III-like domains connected by a hinge region. A 
single hGH molecule interacts with two hGH receptors 
to form the ternary complex hGH:(hGHR)2 [14]. This 
type of complex was used for preliminary modeling of 
the interactions of IL-4 with its receptor [8,15]. In order 
to determine if hlL-4 and hlL-4R truly interact in a 
fashion analogous to the growth hormone system and to 
guide our crystallization efforts, we have undertaken a 
series of experiments to establish the stoichiometry of the 
hIL-4: hIL-4R complex. 
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2. Materials and methods 
2.1. Expression and Purification of hlL-4 
Recombinant hlL-4 used in the gel filtration experiments was ex- 
pressed in a yeast ~t-factor expression system and purified to homogene- 
ity as previously described [16]. This version of recombinant hI IM 
includes the tetrapeptide Glu-Ala-Glu-Ala t the N-terminns. Protein 
was quantified by amino acid composition analysis on a Beckmann 
System 6300 High Performance Analyzer. 
2.2. Preparation of hlL-4 Affinity resin 
An hll.,-4 affinity column was prepared by coupling recombinant 
hIL-4 to Affi-Gel 10 from Bio-Rad (Richmond, CA). Five milliliters of 
Affi-Gel was washed with 10 ml ice cold coupling buffer (25 raM 
NaHCO3/100 mM NaCI, pH 8.5) and then transferred into anice cold 
solution containing 10 nag hlL-4/ml Affi-G-el in coupling buffer (i.e. 50 
mg hIL-4 total). The reaction was incubated at 4"C for 24 h. The 
Affi-Gel was next blocked with 1 M Tris pH 8.0 (0.1 ml buffer/ml 
Affi-Gel) for 1 h at 4"C. The liIL-4 affinity gel was then loaded into 
a column and washed with 3 coltmm volumes of coupling buffer before 
equilibrating for soluble human IL-4R (shlL-4R) purification. The IL-4 
coupling efficiency achieved was 97%. 
2.6. Gel filtration 
Protein samples were run on a pre-packed Pharmacia Hi-Load 16•60 
Superdex 200 gel filtration column with a diameter of 1.6 era and a 
length of 60 era. The column was equilibrated at room temperature in 
50 mM Na phosphate buffer, pH 7.2; the flow rate was maintained at 
1.0 ml/min by a Sehimadzu HPLC pump. The hiant was monitored 
by a UV detector at a wavelength of 280 nm. Pharmacia small molec- 
ular weight protein standards were used to calibrate the column: albu- 
min (67 kDa), ovalbumin (43 kDa), chymotrypsinogen (25 kDa), and 
ribonuclease A (13.7 kDa). A plot of K~ vs. log MW for two standard 
runs resulted in a straight line with a correlation coefficient of 
R 2 = 0.99. K~ was defined as elution volume/column volume. All sam- 
pies were prepared in 50 mM Na phosphate buffer, pH 7.2. The two 
mixtures, 1mol hlL-4:l mol shlL-4R and 1 tool hIL-4:2 tool shlL-4R, 
were prepared at protein concentrations of ~ 1 mg/ml and were allowed 
to equilibrate in the phosphate buffer at room temperature for 15 min 
before being applied to the column. All samples had protein concentra- 
tions between 0.5-1.0 mg protein/ml and sample volumes between 
1-2 ml. 
3. Results 
2.3. Expression of shlL-4R 
A soluble version of human IL-4R (slilL-4R) truncated at the ex- 
tracellular/transmembrane domain junction was expressed in a bacu- 
lovirus/insect cell expression system. The coding sequence for the 
N-terminal 209 residues of hlL-4R was cloned into the NheI site of the 
baculovirus transfer vector pJVPI0 [17]. This vector directs the expres- 
sion of the inserted gene under control of the polyhedrin promoter. 
Recombinant virus was generated after co-transfection of SF9 cells with 
transfer vector and viral DNA. Plaque-purified recombinant virus ex- 
pressing shIL-4R was used to generate high-titer virus stocks. For the 
production of shIl.~4R protein, SF21 or SF9 cells in suspension were 
infected with virus at a multiplicity of 0.5 in serum-free medium (EX- 
CELL 400, JRH Biosciences, Lenexa, KS) and conditioned media con- 
taining secreted protein was harvested 4 days post infection. Unpurified 
conditioned supernatants contained shIL-4R at concentrations be- 
tween 6-20 mg/1. 
2.4. Purification of shll_,-4R 
The 5 ml IL-4 affinity column was equilibrated with at least 5 column 
volumes of 50 mM Na phosphate buffer, pH 7.2. The pH of the bacu- 
lovirus shIL-4R supernatant was adjusted to pH 7.2 with concentrated 
NaOH. Fifty column volumes of the pH-adjusted supernatant was 
passed over the column at a flow rate of 2.5 ml/min. The column was 
then washed with 8 cohmm volumes of 50 mM Na phosphate/1.5 M 
NaCl, pH 7.2, to remove non-specifically bound protein and then with 
an equal volume of 50 mM Na phosphate, pH 7.2, to remove the salt. 
Bound shIL-4R was eluted with 100 mM Na phosphate pH 3.0. The 
ehited shIL-4R was concentrated and de-salted using an Sigma Se- 
phadex G-25 (medium fractionation range) in 10 mM NH4HCOs fol- 
lowed by lyophilization. All steps were performed at 4"C. Protein 
purity was verified by PAGE, Western blot, and N-terminal sequence 
analysis and was quantified by amino acid composition analysis. 
We established the stoichiometry of the complex of 
hlL-4 with shlL-4R by separating mixtures of hlL-4 and 
shlL-4R (in ratios 1 : 1, 1 : 1.5 and 1:2) using gel electro- 
phoresis under native conditions at pH 4.2 (Fig. 1). At 
a 1 : 1 ratio of hIL-4 to shlL-4R, the mixture migrated as 
one single band whose position on the gel was different 
from the position obtained with either hlL-4 or shlL-4R 
alone. This band corresponds therefore to the complex 
ofhlL-4 with shIL-4R. When the ratio of hIL-4 to shlL- 
4R is lower than 1 : 1 (1 : 1.5 in lane 4 and 1:2 in lane 5), 
an excess of free shlL-4R was present as well as the 
complex of hlL-4 with shIL-4R. The same experiment 
has been done at pH 8.8 (using buffer strips at pH 8.8 
and the normal polarity electrode assembly). Under 
these conditions, hIL-4 does not enter into the gel be- 
1 2 3 4 5 
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2.5. Polyacrylamide g l electrophoresis 
The gels were run on a Pharmacia Phast System (Piscataway, NJ) 
under native conditions. Precast 20% homogeneous polyacrylamide 
gels were employed. Due to the high lsoelectric point of hIL-4 
(pI = 9.0), the electrophoretic separation of the protein required acidic 
buffer systems, and the polarity of the electrical field across the gel had 
to be reversed. The acidic conditions were provided by special buffer 
strips prepared with a ~0-alanine acetic buffer pH 4.1 as recommended 
by Pharmacia. These buffer strips in combination with the original 
buffer in PhastGel gave a pH of 4.2 during electrophoresis. The re- 
versed polarity electrode assembly used for the migration was pur- 
chased from Pharmacia. 
All the samples were prepared in 50 mM Na/K phosphate buffer, pH 
7.0, and diluted with an equal volume of Pyromin Y, a tracking dye. 
The various mixtures of hIL-4 and shIL-4R were allowed to equilibrate 
at room temperature for 15 rain before being appfied to the gel. The 
gels were Coomassie stained. 
I L -4  - "  
Fig. 1. Polyacrylamide g l electrophoresls analysis in ative conditions 
at pH 4.2 obtained with mixture of hIL-4 and shIL-4R in varying ratios 
showing that hIL-4 forms a 1:1 complex with the xtracelhilar domain 
of hIL-4R. The gel was run as described in section 2. Lane 1, hIL-4; 
lane 2, shIL-4R; lane 3, mixture of hIL-4 and shIL-4R in an 1:1 ratio; 
lane 4, mixture of hIL4 and shIL-4R in an 1:1.5 ratio; lane 5, mixture 
of hIL-4 and shIL-4R in an 1:2 ratio. 
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Fig. 2. Chromatographs of the gel filtration runs with A~0 on the y-axis and time on the x-axis, tick marks are at 4 rain intervals, a: protein molecular 
weight standards: albumin (67 kDa), ovalbumin (43 kDa), chymotrypsinogen (25 kDa), and ribonuclease A (13.7 kDa); b: hIL-4; c: shIL-4R; d: 1 : 1 
mixture of hIL-4 and shIL-4R; e:1 : 2 mixture ofhIL-4 and shIL-4R. 
cause of its positive charge, but the results obtained with 
the various mixtures of  hIL-4 and shIL-4R are the same 
as the results described previously at pH 4.2 (data not 
shown). 
We utilized gel filtration chromatography as an alter- 
native experimental means to verify the results obtained 
from the native gel analysis. First hIL-4 and shIL-4R 
were run independently on the calibrated Superdex 200 
column to determine their individual apparent molecular 
weights. The molecular weight of recombinant hIL-4 cal- 
culated from its amino acid sequence is 15.4 kDa. The 
cytokine eluted from the column with an apparent mo- 
lecular weight of 16.7 kDa (Table 1). 
The shIL-4R sample resulted in a major peak and a 
minor peak corresponding to ~90% and 10% of the total 
protein (Fig. 2C). The peaks have apparent molecular 
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weights of 37.5 kDa and 71.1 kDa, respectively (Table 
1). Although the smaller molecular weight obtained is 
greater than the molecular weight of shlL-4R calculated 
from its amino acid sequence (23.9 kDa), the protein is 
giycosylated atsix N-linked glycosylation sites and runs 
with an apparent molecular weight of 35-36 kDa on a 
denaturing polyacrylamide gel (data not shown). This 
glycosylated shlL-4R apparent molecular weight is very 
close to the value of 37.5 kDa obtained for the major 
peak. The larger apparent molecular weight of the minor 
peak is in the molecular weight range one would expect 
for a dimer of shlL-4R. When run at 4°C, the major and 
minor peaks are reversed with -90% of the total protein 
running as a dimer (data not shown). 
When a 1:1 mixture of hlL-4 and shlL-4R was run 
over the column, a single peak eluted with an apparent 
molecular weight of 50.9 kDa, indicating all of the pro- 
tein had combined into a single complex. A slight molar 
excess of hlL-4 was noted as a minor peak which eluted 
at 16.6 kDa. When a 1:2 mixture of hlL-4 and shlL-4R 
was run over the column the same peak observed in the 
1 : 1 mixture luted at 46.6 kDa and peaks corresponding 
to excess hlL-4R were also observed at the monomer 
(37.4 kDa) and dimer (74.4 kDa) positions (Fig. 2). No 
peaks were observed with an apparent molecular weight 
greater than shlL-4R dimer as would be expected for a 
1 : 2 complex of hlL-4 to shIL-4R. 
4. Discussion 
These results dearly show that hlL-4 binds to the 
extracellular domain of hlL-4R in a 1 : 1 ratio forming a 
tight monomeric complex, hlL-4:shIL-4R. In this partic- 
Table 1 
Apparent molecular weights obtained from gel filtration chromatogra- 
phy 
Run Average ge a'b Average apparent mol. 
weight (kDa) 
hIL-4 0.762 + 0.026 16.7 (13.7-20.4) c 
shlL-4R (major) 0.659 + 0.023 37.5 (31.2--45.0) monomer 
(minor) 0.577 + 0.027 71.1 (57.5-87.9) dimer 
1 : 1 mixture 
hIL-4:shIL-4R 0.620 + 0.025 50.9 (41.9-61.7) 1 : 1 com- 
plex 
1 : 2 mixture 
hIL-4:shIL-4R 0.659 + 0.023 37.5 (31.2-45.0) monomer 
0.631 + 0.024 46.6 (38.6-56.3) 1 : 1 com- 
plex 
0.571 + 0.028 74.4 (59.9-92.3) dimer 
a All reported values are the averages of two measurements. 
bK~ = protein elution volume/column volume. 
c Uncertainty inK~ value gives associated range of apparent molecular 
weight shown in parantheses. 
ular case, ligand-induced receptor homodimerization as
described for growth hormone [18] does not occur. This 
is not surprising iven recent results which indicate that 
the IL-4:IL-4R complex interacts with a second receptor 
molecule, IL-2R7 [19,20]. 
IL-2R7 appears to be a common component i  the 
receptor complexes for IL-2, IL-4, IL-7 and possibly 
IL-9, IL-13, and IL-15 [19-24]. However, the signalling 
duties are not completely relegated to the common recep- 
tor subunit. In the case of IL-4, it appears that there are 
IL-2Ry-independent signalling events and some IL-2RT- 
dependent events [20,25,26]. Therefore IL-4 should logi- 
cally form a tight 1:1 complex with its specific receptor 
subunit, hlL-4R. 
For cytokines haring a common receptor chain, for- 
mation of a heterodimeric receptor complex will likely be 
the rule rather than receptor homodimerization. Two 
different receptor chains recognizing different epitopes 
on a cytokine is certainly easier to imagine than the 
amazing and unique ease of identical receptor chains 
recognizing disparate cytokine pitopes as observed with 
hGH:(hGHR)2 [14]. Our findings clearly emphasize that 
although the large family of cytokines and their receptors 
are related, the specific ways in which they interact are 
unique. 
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